PrairieView Partners’s CorMedix CRMD Stock Holding History

PrairieView Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-400	Closed	-$4K	–	356
2021 Q1	$4K	Buy	+400	New	+$4.21K	﹤0.01%	313

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PrairieView Partners's CRMD Position: Q2 2021 in Review

PrairieView Partners sold out of CorMedix (CRMD) in Q2 2021, closing a stake of 400 shares — an estimated $4K sold.

PrairieView Partners first reported a position in CRMD in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 79 funds tracked by Wall St. Rank hold CRMD as of Q2 2021.

PrairieView Partners reported no remaining CorMedix position as of Q2 2021 after selling out during the quarter.
PrairieView Partners sold 400 CorMedix shares in Q2 2021, an estimated $4K.
PrairieView Partners first reported a position in CorMedix in Q1 2021 and held it in 1 quarter.
PrairieView Partners's CorMedix position peaked at $4K in Q1 2021.
79 funds tracked by Wall St. Rank held CorMedix as of Q2 2021.

Based on PrairieView Partners's 13F filing for Q2 2021, filed 23 Jul 2021.